-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2015
March 18
NORTHLAND Selected as a Constituent Stock of the First Batch of the New Third Board Index
August 13
Signed a technology transfer agreement with South Korea’s HUONS Company for rhTβ4 technology.
December 15
Recombinant human thymosin β4 has received clinical trial approval (Phase I/II).
December 15
“The Thymosin β4 Derivative and Its Applications” (Patent No. ZL200680025339.0) has been awarded the “China Patent Excellence Award” by the National Intellectual Property Administration.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005